NCT03789110 2026-02-06
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Daiichi Sankyo
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Northwestern University